Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects.

about

Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects.

Item

http://www.wikidata.org/entity/Q42506140

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects.

@en

Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects.

@nl

type

Item

label

Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects.

@en

Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects.

@nl

prefLabel

Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects.

@en

Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects.

@nl

P1476

Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects.

@en

P2093

Huaiqing Wang

http://www.w3.org/2001/XMLSchema#string

Jing Chen

http://www.w3.org/2001/XMLSchema#string

Lingli Zhou

http://www.w3.org/2001/XMLSchema#string

Linong Ji

http://www.w3.org/2001/XMLSchema#string

Qian Ren

http://www.w3.org/2001/XMLSchema#string

Xueyao Han

http://www.w3.org/2001/XMLSchema#string

Yingli Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Efficacy and safety of traditional chinese medicine for diabetes: a double-blind, randomised, controlled trial

The Path to Personalized Medicine

10-year follow-up of intensive glucose control in type 2 diabetes

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Pharmacologic therapy for type 2 diabetes mellitus.

Standards of medical care in diabetes--2007.

Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission.

Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program.

P31

scholarly article

P356

10.1111/1753-0407.12542

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28233424

http://www.w3.org/2001/XMLSchema#string